PF 3392455Alternative Names: PF-3392455
Latest Information Update: 07 Mar 2008
At a glance
- Originator Pfizer
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 28 Feb 2008 Discontinued - Phase-I for Hypertension in USA (unspecified route)
- 31 Jul 2007 Phase I trials in Hypertension in USA (unspecified route)